Rinucumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | platelet-derived growth factor receptor beta |
| Clinical data | |
| Other names | REGN2176 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6472H9974N1710O2022S38 |
| Molar mass | 145309.21 g·mol−1 |
Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.[1][2]
This drug was developed by Regeneron Pharmaceuticals, Inc.
References
- ↑ "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ↑ Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.